Jan. 6, 2004 — Ziconotide is effective in treating pain from cancer or AIDS, according to the results of a double-blind, randomized controlled trial published in the Jan. 7 issue of The Journal ...

Effectiveness of intrathecal ziconotide in malignant pain: A combined analysis of two controlled trials. JCO 24 , 8552-8552 (2006). DOI: 10.1200/jco.2006.24.18_suppl.8552 ...

The active agent ziconotide, the synthetic toxin of the cone snail (Conus magus), was acclaimed a safe alternative to morphine when it was introduced six years ago. Now it is increasingly ...

Intrathecal admixtures containing ziconotide may also be viable treatment options for refractory malignant pain. Methods: The medical records of 5 patients with malignant pain managed with IT ...

The active agent ziconotide, ... being administered to patients with intrathecal pumps if opioids do not suffice or if these trigger inacceptable side effects. Recently, ...

Intrathecal ziconotide provided an opposite response with a positive effect observed on the below-level pain and minimal effect on the at-level pain.

Cancer-related pain affects approximately 9 million people worldwide each year, with the number of new cases expected to increase from 12.7 million in 2008 to 22.2 million by 2030. 1,2 Cancer pain ...

Small, sophisticated, reliable, and controllable implantable pumps, ongoing research, and clinical consensus with respect to the safe delivery of intrathecal medications for chronic pain was the ...

Results from a case series study of 7 patients suggest that treatment with ziconotide may be an effective and safe way to manage MS-related central pain. News & Perspective Drugs & Diseases ...

The Food and Drug Administration (FDA) has issued a safety communication regarding the risks associated with implanted pumps for intrathecal administration of pain medications.

The active agent ziconotide, ... being administered to patients with intrathecal pumps if opioids do not suffice or if these trigger inacceptable side effects. Recently, ...